Navigation Links
Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
Date:7/7/2009

THE WOODLANDS, Texas, July 7 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has initiated a Phase 2 clinical trial of LX1032, the company's oral drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome. LX1032 is designed to reduce serotonin production in patients with metastatic carcinoid tumors. Elevated levels of serotonin contribute to the gastrointestinal and possibly other symptoms experienced by these patients.

In addition to LX1032, Lexicon has three other drug candidates progressing through various stages of clinical development, including LX1031 for irritable bowel syndrome, LX2931 for rheumatoid arthritis, and LX4211 for diabetes. For more information about Lexicon's clinical development programs, please visit www.lexpharma.com.

"This is an important study, designed to evaluate LX1032's effect on the gastrointestinal symptoms experienced by patients with carcinoid syndrome who have become refractory to current treatment options," said Philip M. Brown, M.D., J.D., senior vice president of clinical development at Lexicon. "We are encouraged by the clinical results obtained to date in which LX1032 demonstrated potent reductions in serotonin production in healthy volunteers."

The Phase 2 clinical trial is designed as a four-week, randomi
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
2. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
3. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
4. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
5. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
6. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
7. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
8. Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
9. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
10. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
11. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 2015  Peter Walter wurde als Gewinner ... seine bahnbrechende Arbeit ausgewählt, die sich damit ... sowie für die Entschlüsselung der Komponenten eines ... nutzen, der mit der Ansammlung von deformierten ... Biochemie an der University of California, San ...
(Date:3/27/2015)... -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... platform company serving the global pharmaceutical, biotechnology, and ... New Drug (IND) application for WuXi MedImmune,s novel ... accepted for review by the China Food and ... 2012, MedImmune, the global biologics research and development ...
(Date:3/26/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the ... with certain matters, including the appointment of auditors, its ... 26, 2015 (the "Meeting") was adjourned, as previously disclosed ... 11:00 a.m. ( Toronto time). The ... that previous disclosed. The Meeting will reconvene at the ...
(Date:3/26/2015)... BOSTON , March 26, 2015 /PRNewswire/ ... ), a global clinical research organization ... signed a definitive agreement to acquire all ... India ("QSI"), a leading provider of specialized ... refers to the collection, detection, assessment, monitoring, ...
Breaking Biology Technology:Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3SQI Diagnostics Inc. Announces Adjournment of Meeting 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4
... that a new market research report is available in ... Technologies and Global Markets http://www.reportlinker.com/p0298002/Cancer-Profiling-and-Pathways-Technologies-and-Global-Markets.html ... Cancer Profiling Technologies at about $15 billion in 2009. ... 2010 and $47 billion by 2015, at a compound ...
... BURLINGTON, Mass., Sept. 23 Decision Resources, one ... for pharmaceutical and healthcare issues, finds that growth ... by chronic myelogenous leukemia (CML) therapies (Novartis,s Gleevec ... lymphocytic leukemia (CLL) therapies (Biogen Idec/Roche,s Rituxan and ...
... samples generated during clinical research is rapidly increasing as ... traditional medicine to molecular-based therapeutics. The growing use of ... an increasing emphasis on the value of sample integrity ... collect, store and distribute clinical trial samples. ...
Cached Biology Technology:Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets 2Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets 3Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets 4Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets 5Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets 6Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets 7Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets 8Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets 9Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets 10Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets 11Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets 12Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets 13Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets 14Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets 15Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets 16Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets 17Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon 2BioStorage Technologies Brings Together Industry Leaders for Global Sample Management Benchmarking Symposium 2BioStorage Technologies Brings Together Industry Leaders for Global Sample Management Benchmarking Symposium 3
(Date:3/16/2015)... , March 16, 2015 ... Systems GmbH will present groundbreaking innovations in biometric ... Hanover, Germany .      (Photo: ... latest biometric innovation is well at the forefront: ... generation e-gate made in Germany ...
(Date:3/11/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/3p32qm/access_control ... Control Market by Product, Application & By Geography - ... their offering. , This report predicts that ... billion by 2020, with an estimated CAGR of 10.6%. ... products types such as contact cards & readers, contactless ...
(Date:3/10/2015)... , March 10, 2015  NXT-ID, Inc. (NASDAQ: ... the "Company"), a biometric authentication company focused on ... Wocket™ smart wallet has been named the "Number ... Modern. Rethink Modern ( http://www.rethinkmodern.com/ ) ... for your home and lifestyle that have a unique ...
Breaking Biology News(10 mins):DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4
... climate change will reach a tipping point in less ... health of the planet,s coral reef ecosystems according to ... Released by the Global Coral Reef Monitoring Network and ... partnerships, "Status of Coral Reefs of the World: 2008" ...
... by a Michigan State University chemist could eventually lead ... drugs that are key to treating a number of ... in drug manufacture and research often are made within ... That protein tends to collect into what scientists call ...
... study published in the current issue of CELL ... - fat cells - could become a source for ... , According to the study,s lead researcher, Dr. Yuki ... University School of Medicine, Kawasaki, Japan, adipose-derived stem/stromal cells ...
Cached Biology News:Time running out on coral reefs as climate change becomes increasing threat 2Time running out on coral reefs as climate change becomes increasing threat 3Transplanted fat cells restore function after spinal cord injury 2
Request Info...
... The Fujifilm Life Science FLA-7000 excels ... silver-stained, CBB-stained gel documentation. It features four ... R710, and a filter for Imaging Plates) ... offers a customizable choice of four kinds ...
... Labeling Kit generates labeled cDNA for use ... is made via a reverse transcription from ... Unlike other methods, there are no unnatural ... reaction. This unmodified cDNA is then labeled ...
... enables fully automated hybridization of microarrays on ... been designed to offer researchers improved reproducibility, ... perform a wide range of applications. ... 485C; denaturations of up to 99C. The ...
Biology Products: